Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
599 clinical trials found
Clinical trials

C1071005

MagnetisMM-5: An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Elranatamab (Pf-06863135) Monotherapy And Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone In Participants With Relapsed/Refractory Multiple Myeloma Who Have Received At Least 1 Prior Line Of Therapy Including Lenalidomide And A Proteasome Inhibitor (C1071005) (NCT05020236)

Currently recruiting

C1131003 Pfizer ITP

An International Phase 2, Open-Label, One-Arm, Multi-Center Study to Evaluate Safety and Efficacy of PF-06835375 in Adult Participants with Moderate to Severe Primary Immune Thrombocytopenia (NCT05070845)

Currently recruiting

CA027-002

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (NCT03400332)

No longer recruiting

CA055-026

A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) [CA055-026] (NCT05469737)

Currently recruiting

CA057-001

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (NCT05519085)

Currently recruiting

CA0711000

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor [ARPI], in Participants with Metastatic Castration-resistant Prostate Cancer [mCRPC] - rechARge (NCT06764485)

Currently recruiting

CAAD-VT

Catheter Ablation versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT): A Randomised Trial (ACTRN12620000045910)

Currently recruiting

CADPT07A12101

Phase I, open label, study of B-cell Maturation Antigen (BCMA)-directed CAR-T cells in adult patients with multiple myeloma (NCT04318327)

Currently recruiting

CALIPSO

Multicentre, adaptive, double blind, three arm placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (NCT05447559)

Currently recruiting

CAMBRIA-2

CAMBRIA-2: Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant [AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader] Versus Standard Endocrine Therapy [Aromatase Inhibitor or Tamoxifen] as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (NCT05952557)

Currently recruiting

CAPLA Optional Long Term Follow Up

CAPLA trial: Catheter Ablation for persistent atrial fibrillation: A Multicentre randomised trial of Pulmonary vein isolation (PVI) vs PVI with posterior Left Atrial wall isolation (PWI) (ACTRN12616001436460)

Currently recruiting

CAPRI

Concentrated Albumin infusion Prior to Rescue Infliximab (CAPRI) in steroid refractory Acute Severe Ulcerative Colitis (ASUC), a randomized clinical trial (ACTRN12619001081101p)

Currently recruiting

CARISTA

Creating A Risk assessment biomarker tool to prevent Seasonal and Thunderstorm Asthma – CARISTA Study (NCT07055542)

CARISTA will test a new approach to predict risk for seasonal allergic asthma to identify treatable traits for preventing seasonal allergic asthma exacerbations to reduce the recurrent annual health threat of seasonal and thunderstorm asthma, address community and health care provider concerns and uncertainty regarding preventive treatment and management.
Currently recruiting

CARTITUDE-5

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy - CARTITUDE 5 (NCT04923893)

Currently recruiting

CARTITUDE-6

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (EMN28 68284528MMY3005) (NCT05257083)

Currently recruiting

CASPER

Colchicine After Stroke to Prevent Event Recurrence (CASPER) A randomised trial to evaluate the efficacy of oral Colchicine in high-risk patients with atherosclerosis-associated inflammation post-Stroke (ACTRN12621001408875)

Currently recruiting

CAST BM12

Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and methotrexate to cyclosporin and post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis (ACTRN12618000505202)

Currently recruiting

CC93538-EE-001

A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Eosinophilic Esophagitis (NCT04753697)

No longer recruiting

CC93538-EE-002

A Phase 3, Multicenter, Multinational, Open-label Extension Study to Evaluate the Long-term safety of CC-93538 in Adult and adolescent subjects with eosinophilic esophagitis. (NCT04991935)

Currently recruiting

CCTL019E2301

A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma (NCT05888493)

Currently recruiting
5 6 7 8 9